



Título artículo / Títol article:

Centrally formed acetaldehyde mediates ethanol-induced brain PKA activation

Autores / Autors:

Tarragón Cros, Ernesto ; Baliño Remiro, Pablo ; González Aragón, Carlos Manuel

Revista:

Neuroscience letters

Versión / Versió:

Pre-print

Cita bibliográfica / Cita bibliogràfica (ISO 690):

TARRAGON, E.; BALIÑO, P.; GONZÁLEZ ARAGÓN, C. M. Centrally formed acetaldehyde mediates ethanol-induced brain PKA activation. Neuroscience letters, 2014, vol. 580, p. 68-73.

url Repositori UJI:

<http://hdl.handle.net/10234/127657>

Accepted Manuscript

Title: Centrally Formed Acetaldehyde Mediates
Ethanol-Induced Brain Pka Activation

Author: E. Tarragon P. Baliño C.M.G. Aragon


PII: S0304-3940(14)00627-2
DOI: <http://dx.doi.org/doi:10.1016/j.neulet.2014.07.046>
Reference: NSL 30738

To appear in: *Neuroscience Letters*

Received date: 23-5-2014
Revised date: 24-7-2014
Accepted date: 25-7-2014

Please cite this article as: E. Tarragon, P. Baliño, C.M.G. Aragon, Centrally Formed Acetaldehyde Mediates Ethanol-Induced Brain Pka Activation, *Neuroscience Letters* (2014), <http://dx.doi.org/10.1016/j.neulet.2014.07.046>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Highlights

- EtOH administration in vivo enhances PKA activity in the brain
- cAMP-PKA pathway is involved in the behavioral response to EtOH
- Centrally formed acetaldehyde is responsible for several effects induced by EtOH
- EtOH-induced PKA activation is reduced when central acetaldehyde activity decreases
- cAMP-PKA signaling cascade promoted by EtOH in vivo is dependent on acetaldehyde

Accepted Manuscript

CENTRALLY FORMED ACETALDEHYDE MEDIATES ETHANOL-INDUCED BRAIN PKA ACTIVATION

Tarragon E^{1,2}, Baliño P^{1,2}, Aragon CMG^{1*}

¹ Área de Psicobiología, Universitat Jaume I, Castellon de la Plana (SPAIN); ² Authors

contributed equally to this work

* Corresponding author:

Prof. Carlos M. G. Aragón, PhD
Dept. Psychobiology
Universitat Jaume I
Avinguda Vicent Sos Baynat, s/n
E-12071 Castelló de la Plana (Spain)
Tel.: +34 964729835
aragon@psb.uji.es

Abstract

Centrally formed acetaldehyde has proven to be responsible for several psychopharmacological effects induced by ethanol. In addition, it has been suggested that the cAMP-PKA signaling transduction pathway plays an important role in the modulation of several ethanol-induced behaviors. Therefore, we hypothesized that acetaldehyde might be ultimately responsible for the activation of this intracellular pathway. We used three pharmacological agents that modify acetaldehyde activity (α -Lipoic acid, aminotriazole, and D-penicillamine) to study the role of this metabolite on EtOH-induced PKA activation in mice. Our results show that the injection of α -Lipoic acid, aminotriazole and D-penicillamine prior to acute EtOH administration effectively blocks the PKA-enhanced response to EtOH in the brain. These results strongly support the hypothesis of a selective release of acetaldehyde-dependent Ca²⁺ as the mechanism involved in the neurobehavioral effects elicited by EtOH.

Keywords: acetaldehyde, PKA, ethanol

Introduction

Ethanol (EtOH) is one of the most widely consumed substances of abuse, and yet the molecular mechanism by which it exerts its effects on behavior is still not understood [1]. It is known that EtOH is centrally metabolized into acetaldehyde by a combination of the enzyme catalase and hydrogen peroxide (H₂O₂) [2-4]. This central metabolite has been shown to be responsible for some of the behavioral and neurophysiological effects elicited by EtOH [5,6]. In this sense, there is evidence showing that the manipulation of central acetaldehyde through the α -Lipoic acid (LA) scavenging of H₂O₂ [7-10], the catalase inhibition by 3-amino-1,2,4-triazole (aminotriazole, AT) [3,11-13], and acetaldehyde inactivation by D-penicillamine (D-Pen) [14-18] are capable of preventing different behavioral outcomes resulting from acute EtOH exposure.

The cAMP-PKA cellular signaling pathway has been described as an important mechanism involved in the neurobiological response to EtOH [19,20]. There is evidence in vitro and in vivo showing an activation of the cAMP signaling cascade following EtOH exposure [21-24]. In addition, it has been demonstrated that manipulations of the cAMP-PKA pathway modulate some of the EtOH-induced responses at the behavioral level [25,26]. Therefore, the PKA activity elicited by EtOH has been suggested as critical in some behavioral effects induced by this alcohol. However, the particular mechanism by which this EtOH/cAMP-PKA interaction occurs has not yet been clarified in detail.

Considering that acetaldehyde has proven to be responsible for many different EtOH-induced behaviors, and that this alcohol activates the cAMP-PKA signaling pathway, we hypothesized that acetaldehyde might be ultimately responsible for the activation of this intracellular pathway. Hence, we aimed to study the role of central acetaldehyde on EtOH-induced PKA activation. To do this, we used different pharmacological agents that have previously proven effective in preventing central acetaldehyde formation following EtOH administration, such as LA [7,9,27], AT [12-14], and D-Pen [16,18]. We have assessed whether these pharmacological manipulations alter the PKA activity induced by EtOH administration.

PKA activity was evaluated taking into consideration the results of such activation using a subset of phosphorylatable substrate consensus motifs as a kinase footprint [23,24].

Material and methods

Animals

For this work, we used a total of 4–6 male CD-1 mice (Harlan, Interfauna) per group. All animals, aged 4–6 weeks upon arrival, were housed 3 per cage in an acclimated quarantine room, in which they remained for a week. After this quarantine period, mice were moved into a colony room at least one week before the experiments started. The colony room was maintained at a temperature of $21 \pm 1^\circ\text{C}$ and controlled under a 12-h light/dark cycle (lights on at 8 a.m.). Food and water were provided ad libitum throughout the study. All experimental procedures complied with the European Community Council Directive (2010/63/EU).

Drugs

EtOH, purchased from Panreac (Barcelona, Spain), was diluted to 20% (v/v) in 0.9% (w/v) physiological saline, which was also used as the vehicle. LA (Sigma-Aldrich Química, Madrid, Spain) was dissolved in Dulbecco's phosphate-buffered saline, using a minimum possible amount of 1 M NaOH solution. The final pH of the resulting solution was 7 ± 1 . AT and D-Pen (Sigma-Aldrich Química, Madrid, Spain) were both diluted in 0.9% (w/v) physiological saline.

Experimental procedure

All animals ($n = 4\text{--}6$ per group) were moved from their home cages to the procedure room 30 minutes before the start of the experiment to allow them to acclimatize to the environmental conditions. Three different experimental phases were conducted. In the first experiment, animals were pretreated with LA (0 or 100 mg/Kg, i.p.), and 30 minutes later EtOH (0 or 2.5 g/Kg, i.p.) was injected [7]. In the second experiment, AT (0 or 1 g/Kg, i.p.) was administered 4h prior to the EtOH challenge (0 or 2.5 g/Kg, i.p.) [12]. Lastly, in the third

experiment D-Pen (0 or 75 mg/Kg, i.p.) was administered 30 minutes before EtOH (0 or 2.5 g/Kg, i.p.) injection [14]. For all three experimental phases, animals were sacrificed 15 minutes after EtOH administration. Brains were immediately removed and dissected. PKA activity was measured using a subset of phosphorylatable substrate consensus motifs as a kinase footprint [23,24].

Western blot

For determination of PKA, 20 µg of protein extract from three brain structures (frontal cortex, striatum and hypothalamus; n = 4–6 per group) were run in duplicate into pure nitrocellulose membranes (0.45 mm) using standard techniques. Membranes were incubated overnight with a primary antiphosphorylated PKA substrate motif (1:6,000; Cell Signaling Technology, Beverly, MA) and then with HRP-conjugated secondary antibody anti-rabbit (1:20,000). Anti-GAPDH antibody (1:40,000; Sigma-Aldrich Química) was used as a loading control. Proteins were visualized using an enhanced chemi-luminescence system (Amersham Pharmacia Biotech, Madrid, Spain). The relative intensities were quantified and analyzed individually with Sigma-Gel image analysis software version 1.0 (Jandel Scientific, Madrid, Spain). Density values were averaged to obtain a normalized value. The average of these normalized values in the saline-treated group was arbitrarily considered to be 100% and then used for calculations involving all the different experimental manipulations.

Statistical analysis

For the analysis, the relative increase was considered to be the dependent variable. A one- or two-way ANOVA was performed when required. Newman-Keuls post hoc comparisons were used in experiments 1 and 3. The Tukey HSD post hoc test was applied in the analyses of the results obtained in experiment 2 because it is highly conservative against type I error and it does not require a significant interaction between factors [28]. All statistical analyses were performed using the Statistica 9.0 (StarSoft, Tulsa, OK, USA) software package.

Results

PKA activation after the administration of α -lipoic acid

In this experiment, we assessed the role of the catalase-H₂O₂ system in the EtOH-induced activation of the PKA. Pretreatment with the H₂O₂ scavenger LA resulted in a decreased intensity of the immunoreactive bands in all the structures in the study. Figure 1 reflects the effects of LA pretreatment on the EtOH-induced activation of PKA on the cortex (A), striatum (B), and hypothalamus (C). Two-way ANOVA (pretreatment x treatment) showed a lack of effect both for pretreatment and treatment factor in cortex and striatum. A significant main effect was found for the treatment [$F(1,18) = 11.25, p < 0.01$] and pretreatment [$F(1,18) = 19.03, p < 0.01$] factor in the hypothalamus. Both factors (pretreatment x treatment) interact in all the structures of the study: the cortex [$F(1,17) = 7.76, p < 0.05$], striatum [$F(1,18) = 10.27, p < 0.01$] and hypothalamus [$F(1,18) = 13.69, p < 0.01$]. Post hoc comparisons indicate an activating effect of the PKA after EtOH injection when compared to its saline control for cortex ($p < 0.05$), striatum ($p < 0.05$), and hypothalamus ($p < 0.01$). Furthermore, no statistical differences were found in the PKA fingerprint among groups pretreated with LA for all the structures in the study.

PKA activation after the administration of aminotriazole

Here, we have studied the role of the catalase-H₂O₂ system in EtOH-induced activation of PKA. Pretreatment with the catalase inhibition agent AT resulted in a reduction in the PKA activity elicited by EtOH. Figure 2 shows the effect of AT administration on the PKA fingerprint in (A) cortex, (B) striatum, and (C) hypothalamus. Two-way ANOVA (pretreatment x treatment) showed a significant main effect for EtOH treatment in the cortex [$F(1,18) = 5.71, p < 0.05$] and hypothalamus [$F(1,18) = 10.40, p < 0.05$]. The pretreatment factor was found to be significant in the hypothalamus [$F(1,18) = 6.66, p < 0.05$]. An interaction effect (pretreatment x treatment) was also found in the striatum [$F(1,17) = 8.62, p < 0.05$].

However, no significant interaction was found for the cortex [$F(1,18) = 2.51$] or the hypothalamus [$F(1,18) = 2.55$]. Thus, we selected Tukey's HSD post hoc comparisons to analyze the three structures in this experiment. Tukey's HSD post hoc analyses demonstrated that pretreatment with EtOH increased PKA activity for all the structures in the study. Moreover, no statistical differences were found among groups pretreated with AT.

PKA activation after the administration of D-penicillamine

Here, we aimed to study the role of centrally formed acetaldehyde on ethanol-elicited PKA activation. Pretreatment with the acetaldehyde inactivating agent D-pen produced a reduction in the EtOH-induced activation of PKA. Figure 3 reflects the effect of D-pen administration on EtOH-activated PKA in (A) cortex, (B) striatum, and (C) hypothalamus. Two-way ANOVA (pretreatment x treatment) showed a significant main effect for EtOH treatment in all the structures in the study, i.e., the cortex [$F(1,15) = 25.77$, $p < 0.01$], striatum [$F(1,18) = 12.58$, $p < 0.01$], and hypothalamus [$F(1,22) = 5.19$, $p < 0.05$]. Moreover, D-pen pretreatment was found to be significant in the cortex [$F(1,15) = 26.35$, $p < 0.01$], striatum [$F(1,18) = 15.43$, $p < 0.01$], and hypothalamus [$F(1,22) = 15.78$, $p < 0.01$]. Both factors (pretreatment x treatment) interact in the cortex [$F(1,15) = 10.22$, $p < 0.01$], striatum [$F(1,18) = 13.52$, $p < 0.01$], and hypothalamus [$F(1,22) = 12.83$, $p < 0.01$]. Post hoc comparisons indicate an activating effect of PKA after EtOH injection when compared to its saline control for all the structures in the study, $p < 0.01$. Furthermore, no significant differences were found among groups pretreated with D-pen.

Discussion

In this work, we aimed to explore the role of centrally formed acetaldehyde on EtOH-induced activation of PKA. In agreement with previously published data [23,24], our results show that EtOH administration to mice elicited PKA activation in different brain areas (prefrontal

cortex, striatum, and hypothalamus). Catalase-H₂O₂ system blockade by pretreatment with LA and AT resulted in a reduction in EtOH-induced activation of PKA. Furthermore, pretreatment with the acetaldehyde inactivator D-Pen also produced a decrease in PKA activity observed after EtOH administration. These data suggest a role of centrally formed acetaldehyde in EtOH-elicited PKA activation.

The effects of EtOH on PKA activity have been shown in neuronal cell cultures [29,30]. Again, *in vivo* experiments have demonstrated an up-regulation of the cAMP-PKA cascade after EtOH administration [22,23,31]. In the present work, we aimed to explore the functional consequences of brain acetaldehyde modulation on EtOH-stimulated PKA activity. Thus, we have used a subset of phosphorylatable consensus motifs as a PKA-activated fingerprint [22,23]. Previous literature has demonstrated that EtOH administration promotes an increased steady response at different band intensities (90, 100 and 140 kDa) in mice brains [22,23]. Consistent with these results, we have found a similar band-enhanced response after EtOH administration in the areas in the study. Conversely, when acetaldehyde manipulations were administered prior to EtOH, the densitometric analysis indicated a reduction in the band intensity when compared to control animals. These data suggest that centrally formed acetaldehyde is critical to further activate the cAMP-PKA cascade promoted by EtOH exposure.

Acetaldehyde has been suggested as a neuroactive agent responsible for different EtOH neurobehavioral effects [32]. Thus, in order to ascertain the role of acetaldehyde in EtOH-induced activation of PKA, we have used three pharmacological approaches. Firstly, we have used LA as an H₂O₂ scavenging agent. This compound acts as an H₂O₂ scavenger and it has been demonstrated that, if administered systemically, it modulates brain H₂O₂ levels, and consequently catalase activity [7,27]. Secondly, we used the noncompetitive catalase inhibitor AT. This compound can also be administered systemically, and prevents acetaldehyde formation after EtOH administration [3,33]. Finally, we have used the acetaldehyde-sequestering agent D-Pen, which prevents interaction between the centrally formed

acetaldehyde and the neural substrate [14,15,17]. Despite the fact that these agents differed in their molecular mechanism of action to block acetaldehyde production, our results showed that EtOH metabolism at a central level appears to be critical to elicit further PKA activation.

A great body of evidence has demonstrated that the activation of the cAMP signaling cascade appears to be a major cellular response to EtOH *in vivo* and in different cell preparations [21,23,30]. However, the particular mechanism by which this activation occurs has still not been clarified in detail. In this respect, recently published data from our laboratory have demonstrated that intracellular calcium (Ca^{2+}) appears to be a key factor in this EtOH-induced PKA activation [34-36]. Thus, different manipulations addressed to modulate intracellular Ca^{2+} levels resulted in a selective blockade of the PKA response elicited by EtOH [34]. Interestingly, it has been found that acetaldehyde administration at biologically relevant concentrations ranging from 1–10 μM promotes Ca^{2+} release in different cell preparations [37-40]. Moreover, these authors also found that manipulations affecting EtOH oxidation to acetaldehyde were able to modulate such acetaldehyde-mediated Ca^{2+} release.

At the behavioral level, the PKA signaling transduction pathway has proven to be involved in the modulation of several EtOH-induced behaviors. Manipulations of the cAMP-PKA-dependent cascade modulate EtOH intake [24], EtOH-induced sensitization [26,41], and EtOH sensitivity [42]. In this regard, previous work by our group has demonstrated that the alteration of cytoplasmic Ca^{2+} levels reduced EtOH intake, EtOH-induced locomotor activity, and affected EtOH sensitivity [34,35]. Given this, it has been suggested that intracellular Ca^{2+} levels may be a key factor that determines the cAMP-signaling response, and consequently the behavioral outcome observed after EtOH administration.

Parallel to these interesting findings, a great body of evidence has proven that central acetaldehyde plays a key role in different EtOH-promoted behaviors. Thus, manipulations focused on decreasing or blocking acetaldehyde production, such as catalase inhibition by the use of AT or acetaldehyde sequestration with the agent D-Pen, resulted in a reduction in EtOH-

induced locomotor activity [14,17], EtOH intake [15], EtOH-induced place preference [15,27], social recognition [43], loss of righting reflex [44], and anxiety [45]. Furthermore, a reduction of the brain levels of compound I by the pharmacological manipulation of the cellular oxidative state also played a critical role in the behavioral response promoted by EtOH. H₂O₂ scavenging with LA or Ebselen have proven to modulate EtOH-induced locomotor activity [7,36], EtOH intake [8], and EtOH-induced conditioned place preference [27].

In sum, we demonstrate that, when administered previously, acetaldehyde inactivation agents effectively inhibit PKA activation following EtOH exposure. Therefore, this work provides valuable insight into the putative intracellular mechanism through which EtOH might be exerting its effects. Moreover, these data support the idea that, through the PKA-involved intracellular Ca²⁺ pathway, centrally formed acetaldehyde is mainly responsible for the appearance of the psychopharmacological effects of EtOH.

Conclusion

We have demonstrated that the activation of the cAMP-PKA signaling cascade promoted by EtOH administration in vivo is dependent on the central catalasemic metabolism of EtOH. Thus, manipulations, which reduced the rate of centrally formed acetaldehyde, resulted in a decreased EtOH-induced activation of PKA. Moreover, all these results together with the previous literature strongly support the hypothesis of a selective release of acetaldehyde-dependent Ca²⁺ from the ER as the mechanism involved in the neurobehavioral effects elicited by EtOH.

Acknowledgements

This research was supported by a grant from the Spanish *Ministerio de Ciencia e Innovacion* (PSI2011-28934/ PSIC). Pablo Baliño was supported by a fellowship from the CICYT (BES-2009-024438). Ernesto Tarragon was supported at the time by *Red de Trastornos Adictivos, Ministerio de Sanidad y Política Social* (RD06/0001/0028), Spain.

References

1. R.A. Harris, J.R. Trudell, S.J. Mihic, Ethanol's molecular targets, *Science signaling* 1 (2008) re7.
2. J.F. Cohen, J.A. Elberling, E.G. DeMaster, R.C. Lin, H.T. Nagasawa, N-Terminal dipeptides of D(-)-penicillamine as sequestration agents for acetaldehyde, *Journal of medicinal chemistry* 43 (2000) 1029-1033.
3. C.M.G. Aragon, F. Rogan, Z. Amit, Ethanol metabolism in rat brain homogenates by a catalase-H₂O₂ system, *Biochemical pharmacology* 44 (1992) 93-98.
4. S.M. Zimatkin, A.L. Buben, Ethanol oxidation in the living brain, *Alcohol and alcoholism* 42 (2007) 529-532.
5. X.S. Deng, R.A. Deitrich, Putative role of brain acetaldehyde in ethanol addiction, *Current drug abuse reviews* 1 (2008) 3-8.
6. L. Hipolito, M.J. Sanchez, A. Polache, L. Granero, Brain metabolism of ethanol and alcoholism: an update, *Current drug metabolism* 8 (2007) 716-727.
7. J.C. Ledesma, C.M.G. Aragon, alpha-Lipoic acid, a scavenging agent for H₂O₂, reduces ethanol-stimulated locomotion in mice, *Psychopharmacology* 219 (2012) 171-180.
8. J.C. Ledesma, P. Balino, C.M.G. Aragon, Reduction in central H₂O₂ levels prevents voluntary ethanol intake in mice: a role for the brain catalase-H₂O₂ system in alcohol binge drinking, *Alcoholism, clinical and experimental research* 38 (2014) 60-67.
9. A.T. Peana, G. Muggironi, G. Fois, M. Diana, Alpha-lipoic acid reduces ethanol self-administration in rats, *Alcoholism, clinical and experimental research* 37 (2013) 1816-1822.
10. M. Melis, E. Carboni, P. Caboni, E. Acquas, Key role of salsolinol in ethanol actions on dopamine neuronal activity of the posterior ventral tegmental area, *Addiction biology* (2013).

11. C.M.G. Aragon, Z. Amit, The effect of 3-amino-1,2,4-triazole on voluntary ethanol consumption: evidence for brain catalase involvement in the mechanism of action, *Neuropharmacology* 31 (1992) 709-712.
12. D. Escarabajal, M. Miquel, C.M.G. Aragon, A psychopharmacological study of the relationship between brain catalase activity and ethanol-induced locomotor activity in mice, *Journal of studies on alcohol* 61 (2000) 493-498.
13. L. Font, M. Miquel, C.M.G. Aragon, Involvement of brain catalase activity in the acquisition of ethanol-induced conditioned place preference, *Physiology & behavior* 93 (2008) 733-741.
14. L. Font, M. Miquel, C.M.G. Aragon, Prevention of ethanol-induced behavioral stimulation by D-penicillamine: a sequestration agent for acetaldehyde, *Alcoholism, clinical and experimental research* 29 (2005) 1156-1164.
15. A. Orrico, L. Hipolito, M.J. Sanchez-Catalan, L. Marti-Prats, T. Zornoza, L. Granero, A. Polache, Efficacy of D-penicillamine, a sequestering acetaldehyde agent, in the prevention of alcohol relapse-like drinking in rats, *Psychopharmacology* 228 (2013) 563-575.
16. A.T. Peana, P. Enrico, A.R. Assaretti, E. Pulighe, G. Muggironi, M. Nieddu, A. Piga, A. Lintas, M. Diana, Key role of ethanol-derived acetaldehyde in the motivational properties induced by intragastric ethanol: a conditioned place preference study in the rat, *Alcoholism, clinical and experimental research* 32 (2008) 249-258.
17. L. Marti-Prats, M.J. Sanchez-Catalan, L. Hipolito, A. Orrico, T. Zornoza, A. Polache, L. Granero, Systemic administration of D-penicillamine prevents the locomotor activation after intra-VTA ethanol administration in rats, *Neuroscience letters* 483 (2010) 143-147.
18. S.M. March, P. Abate, N.E. Spear, J.C. Molina, The role of acetaldehyde in ethanol reinforcement assessed by Pavlovian conditioning in newborn rats, *Psychopharmacology* 226 (2013) 491-499.

19. E. Quertemont, S. Tambour, P. Bernaerts, S.M. Zimatkin, E. Tirelli, Behavioral characterization of acetaldehyde in C57BL/6J mice: locomotor, hypnotic, anxiolytic and amnesic effects, *Psychopharmacology* 177 (2004) 84-92.
20. L.H. Jiang, J. Wang, X.L. Wei, Q.Y. Liang, T.T. Cheng, Exogenous sodium hydrosulfide can attenuate naloxone-precipitated withdrawal syndromes and affect cAMP signaling pathway in heroin-dependent rat's nucleus accumbens, *European review for medical and pharmacological sciences* 16 (2012) 1974-1982.
21. I. Diamond, A.S. Gordon, Cellular and molecular neuroscience of alcoholism, *Physiological reviews* 77 (1997) 1-20.
22. J.W. Maas, Jr., S.K. Vogt, G.C. Chan, V.V. Pineda, D.R. Storm, L.J. Muglia, Calcium-stimulated adenylyl cyclases are critical modulators of neuronal ethanol sensitivity, *The Journal of neuroscience : the official journal of the Society for Neuroscience* 25 (2005) 4118-4126.
23. P. Balino, J.C. Ledesma, C.M.G. Aragon, In vivo study of ethanol-activated brain protein kinase A: manipulations of Ca²⁺ distribution and flux, *Alcoholism, clinical and experimental research* 38 (2014) 629-640.
24. G. Wand, M. Levine, L. Zweifel, W. Schwindinger, T. Abel, The cAMP-protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol, *The Journal of neuroscience : the official journal of the Society for Neuroscience* 21 (2001) 5297-5303.
25. S.C. Pandey, H. Zhang, A. Roy, T. Xu, Deficits in amygdaloid cAMP-responsive element-binding protein signaling play a role in genetic predisposition to anxiety and alcoholism, *The Journal of clinical investigation* 115 (2005) 2762-2773.
26. D.M. Hayes, J.R. Fee, T.J. McCown, D.J. Knapp, G.R. Breese, I. Cubero, F. Carvajal, J.M. Lerma-Cabrera, M. Navarro, T.E. Thiele, Neuropeptide Y signaling modulates the

- expression of ethanol-induced behavioral sensitization in mice, *Addiction biology* 17 (2012) 338-350.
27. J.C. Ledesma, C.M.G. Aragon, Acquisition and reconditioning of ethanol-induced conditioned place preference in mice is blocked by the H₂O₂ scavenger alpha lipoic acid, *Psychopharmacology* 226 (2013) 673-685.
28. G.M. Wilcox, J.R. Beck, Early invasive cancer in adenomatous colonic polyps ("malignant polyps"). Evaluation of the therapeutic options by decision analysis, *Gastroenterology* 92 (1987) 1159-1168.
29. D.P. Dohrman, I. Diamond, A.S. Gordon, Ethanol causes translocation of cAMP-dependent protein kinase catalytic subunit to the nucleus, *Proceedings of the National Academy of Sciences of the United States of America* 93 (1996) 10217-10221.
30. O. Asher, T.D. Cunningham, L. Yao, A.S. Gordon, I. Diamond, Ethanol stimulates cAMP-responsive element (CRE)-mediated transcription via CRE-binding protein and cAMP-dependent protein kinase, *The Journal of pharmacology and experimental therapeutics* 301 (2002) 66-70.
31. J. Li, Y.H. Li, X.R. Yuan, Changes of phosphorylation of cAMP response element binding protein in rat nucleus accumbens after chronic ethanol intake: naloxone reversal, *Acta pharmacologica Sinica* 24 (2003) 930-936.
32. M. Correa, J.D. Salamone, K.N. Segovia, M. Pardo, R. Longoni, L. Spina, A.T. Peana, S. Vinci, E. Acquas, Piecing together the puzzle of acetaldehyde as a neuroactive agent, *Neuroscience and Biobehavioral Reviews* 36 (2012) 404-430.
33. J.C. Ledesma, L. Font, C.M.G. Aragon, The H₂O₂ scavenger ebselen decreases ethanol-induced locomotor stimulation in mice, *Drug and alcohol dependence* 124 (2012) 42-49.

34. E. Tarragon, P. Balino, C.M.G. Aragon, Dantrolene blockade of ryanodine receptor impairs ethanol-induced behavioral stimulation, ethanol intake and loss of righting reflex, *Behavioural brain research* 233 (2012) 554-562.
35. P. Balino, L. Monferrer, R. Pastor, C.M.G. Aragon, Intracellular calcium chelation with BAPTA-AM modulates ethanol-induced behavioral effects in mice, *Experimental neurology* 234 (2012) 446-453.
36. P. Balino, J.C. Ledesma, C.M.G. Aragon, Role of Ca²⁺/Calmodulin on ethanol neurobehavioral effects, *Psychopharmacology* (in press) (2014).
37. T. Oba, T. Ishikawa, T. Murayama, Y. Ogawa, M. Yamaguchi, H₂O₂ and ethanol act synergistically to gate ryanodine receptor/calcium-release channel, *American journal of physiology. Cell physiology* 279 (2000) C1366-1374.
38. T. Oba, Y. Maeno, Acetaldehyde alters Ca²⁺-release channel gating and muscle contraction in a dose-dependent manner, *American journal of physiology. Cell physiology* 286 (2004) C1188-1194.
39. A. Gonzalez, J.A. Pariente, G.M. Salido, Ethanol stimulates ROS generation by mitochondria through Ca²⁺ mobilization and increases GFAP content in rat hippocampal astrocytes, *Brain research* 1178 (2007) 28-37.
40. T. Oba, Y. Maeno, M. Nagao, N. Sakuma, T. Murayama, Cellular redox state protects acetaldehyde-induced alteration in cardiomyocyte function by modifying Ca²⁺ release from sarcoplasmic reticulum, *American journal of physiology. Heart and circulatory physiology* 294 (2008) H121-133.
41. B.K. Tolliver, L.B. Ho, L.M. Fox, S.P. Berger, Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventricular tegmental area amphetamine, *The Journal of pharmacology and experimental therapeutics* 289 (1999) 38-47.

42. T.E. Thiele, B. Willis, J. Stadler, J.G. Reynolds, I.L. Bernstein, G.S. McKnight, High ethanol consumption and low sensitivity to ethanol-induced sedation in protein kinase A-mutant mice, *The Journal of neuroscience : the official journal of the Society for Neuroscience* 20 (2000) RC75.
43. H.M. Manrique, M. Miquel, C.M.G. Aragon, Brain catalase mediates potentiation of social recognition memory produced by ethanol in mice, *Drug and alcohol dependence* 79 (2005) 343-350.
44. M. Correa, C. Sanchis-Segura, C.M.G. Aragon, Influence of brain catalase on ethanol-induced loss of righting reflex in mice, *Drug and alcohol dependence* 65 (2001) 9-15.
45. M. Correa, H.M. Manrique, L. Font, M.A. Escrig, C.M.G. Aragon, Reduction in the anxiolytic effects of ethanol by centrally formed acetaldehyde: the role of catalase inhibitors and acetaldehyde-sequestering agents, *Psychopharmacology* 200 (2008) 455-464.

Figure 1. PKA activation after LA administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with LA (0 or 100 mg/kg, i.p.) 30 minutes before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean \pm SEM. * $p < 0.05$, ** $p < 0.01$ significantly different from its respective Vehicle control. S, saline; E, EtOH; LA, α -lipoic acid.

Figure 2. PKA activation after AT administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with AT (0 or 1 g/kg, i.p.) 4 hours before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean \pm SEM. * $p < 0.05$, ** $p < 0.01$ significantly different from its respective Vehicle control;. S, saline; E, EtOH; AT, aminotriazole.

Figure 3. PKA activation after D-Pen administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with D-Pen (0 or 75 mg/kg, i.p.) 30 minutes before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean \pm SEM. ** $p < 0.01$ significantly different from its respective Vehicle control. S, saline; E, EtOH; D-Pen, D-penicillamine.

Figure 1






Figure 2






Figure 3

